B. Fellman

SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA 9)

F. Meric-Bernstam, A. Naing, K. Kurnit, 2023, Gynecologic Oncology.

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

A. Knisely, Reshma A. Rangwala, Emily Hinchcliff, 2024, iScience.